Back to Treatments

Treatment

Extended Half-Life (EHL) Recombinant Factor IX

1
Conditions
40
Trials
6,000
Participants
68%
Average Safety

Condition Evidence

Hemophilia

40 trials · 6,000 participants

90% effectiveness · 68% safety
Extended Half-Life (EHL) Recombinant Factor IX | DFDA